Marinus Pharma (MRNS) Reports In-Line Q4 EPS
Tweet
Share
E-mailGet Alerts MRNS Hot Sheet
Join SI Premium – FREE
Marinus Pharma (NASDAQ: MRNS) reported Q4 EPS of ($0.77), in-line with the analyst estimate of ($0.77). Revenue for the quarter came in at $1.52 million versus the consensus estimate of $3.46 million.
For earnings history and earnings-related data on Marinus Pharma (MRNS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ASML Holdings (ASML) Tops Q2 EPS by 59c; offers guidance
- UBS Downgrades Allstate (ALL) to Neutral
- Oppenheimer Downgrades IBM (IBM) to Perform
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
